Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shilpa Medicare Limited ( (IN:SHILPAMED) ) has provided an announcement.
Shilpa Medicare Limited announced the completion of a USFDA inspection at its Unit IV facility in Jadcherla, Telangana, which resulted in eight observations but no repeat issues. The facility’s contribution to the company’s US sales is minimal, accounting for less than 1% of the total business for the first half of FY25-26. The company plans to address the observations comprehensively within the stipulated timeframe, maintaining its compliance with international regulatory standards.
More about Shilpa Medicare Limited
Shilpa Medicare Limited operates in the pharmaceutical industry, focusing on the manufacturing, packaging, testing, storage, and distribution of sterile injectables, oral tablets, and capsules. The company serves markets in the US, Europe, and other global regions and is approved by major regulators such as EMA, Health Canada, Anvisa, and TGA.
Average Trading Volume: 27,900
Technical Sentiment Signal: Hold
Current Market Cap: 70.76B INR
See more insights into SHILPAMED stock on TipRanks’ Stock Analysis page.